JUMP TO CONTENT

How has the pharmaceuticals industry changed in the last decade?

Posting date: 23/04/2020
Author: Inside ICON
The pharmaceuticals industry has been revolutionised over the last decade due to advances in technology and globalisation – and with it have come changes in clinical research. However, the US has maintained its majority share of the market and oncology remains the most valuable branch of therapy.

As for the public’s involvement, they’re becoming increasingly aware of the drugs they’re being prescribed which has pushed pharma companies to develop a more personalised level of treatment in the form of precision medicine. These factors are the key driving forces behind the growth of the industry over the last decade and we only expect this to continue, which means the future is bright for clinical research professionals.

Here’s an overview of an exciting decade in pharmaceuticals.

Digital is revolutionising pharmaceuticals

Like every industry, pharmaceuticals has been transformed by digital technologies. Predictive analytics, big data analytics and AI-based tools have given companies the tools they need to redesign their business processes. Using this new information to create a revived business model means that companies can produce drugs faster than ever before while artificial intelligence has enabled us to improve a patient’s responsiveness to drugs. The industry hasn’t missed out on tapping into the app market – according to Deloitte, from 2013 to 2016 pharma companies tripled the number of apps they developed. This is one example of how we’ve seen pharma shift towards being more patient-centric as these apps allow the public the be more in control of their health and engage better with companies on patient platforms.

Further to this, the current pandemic has transformed the industry at all levels, leaving many questions, such as, 'Could remote decentralised clinical trials be the future?'

Globalisation of pharma

As we entered the 2010s, we witnessed products for drugs being sourced and manufactured internationally, then sold on a global market platform – this globalisation is a first for the pharmaceuticals industry. Before this decade there were several R&D hubs but from 2010 onwards this shifted towards a global outsourcing of research capabilities and the mass manufacturing of drugs for both the developed and developing markets. This globalisation means that the CIVET group - Cambodia, Indonesia, Vietnam, Egypt and Turkey - now have access to drugs, which is one major contributor to the growth of the pharmaceutical industry.

A decade of growth for pharma

It was announced in 2018 that the global pharmaceuticals market had cashed $1.2 trillion in revenue, which is a soaring 35% increase in just 10 years. America continues to have the biggest impact on this figure for various reasons, including lower taxes on drugs, a drop in prices and more relaxed regulatory barriers for new drugs.

Globally, we’re experiencing an ageing population who are presenting more complex health conditions which need medication. In 2010 China was the third largest pharmaceutical market and since then they’ve climbed up to second place, only behind the US, which remains a leader in clinical research. A key reason for this rise in the ranks is that in 2019, between August and November, their drug reimbursement list added 218 new medicines.

As the list continues to grow we expect the Chinese pharmaceuticals market to continue booming and helping the overall marketing grow from strength to strength.

Prescription medicines

In 2019 spending on prescription drugs hit US$500 billion, reflecting a two-fold increase in the last 10 years. Yet, according to Market Watch, 2019 also marked the first time in 47 years the price of prescription medicine has dropped, falling 6% lower than the price in 2010. The makeup of these drugs has transformed over the decade too, starting as small molecule or biologics and switching to in silico in 2010. This was a step towards developing treatments that were personalised for each patient and enabled the introduction of cell-based and gene-based therapies in 2011 and 2012 respectively.

The advent of precision medicine

Precision medicine considers a person’s genes, environment and lifestyle to predict which treatment will be most effective. The defining feature of this practice of medicine is the focus on genomic data to design the specific treatment paths - in other words, the study of how a person will respond to a drug based on their genetic makeup.

The advent of precision medicine has allowed the development of effective and safe medication that is tailored to the individual, thereby helping to improve the health of people who are not responding to standardised options. But pharma companies are only just scratching the surface of precision medicine as it’s expected that by 2025 the market will be worth US$85.5 billion.

Join us for another exciting decade in pharmaceuticals

If you want to work with the world’s top pharma, biotechnology and medical device companies, bring your career to ICON. We’re a leading clinical research organisation and are always looking for talented and driven people to help us become the partner of choice in drug development, particularly those who are clinical research associates.

View our clinical research jobs or browse all job categories to narrow your search.


List #1

Related jobs at ICON

Clinical Research Associate - Sponsor dedicated

Salary

Location

Germany, Frankfurt

Location

Frankfurt

Remote Working

Remote

Business Area

ICON Strategic Solutions

Job Categories

Clinical Monitoring

Job Type

Permanent

Description

We are currently seeking a Clinical Research Associate II to join our diverse and dynamic team. As a Clinical Research Associate II at ICON, you will play a pivotal role in designing and analyzing cli

Reference

JR137871

Expiry date

01/01/0001

Roxana Rosca

Author

Roxana Rosca
Read more Shortlist Save this role
Quality Assurance Auditor II

Salary

Location

Netherlands, Assen

Department

Full Service - Quality Assurance

Location

Assen

Remote Working

Office Based

Business Area

ICON Full Service & Corporate Support

Job Categories

Quality Assurance

Job Type

Permanent

Description

The Early Development Services (EDS) division of ICON is a global leader in providing early-phase clinical research (phase I and IIa) and bioanalytical services to the pharmaceutical and biotechnology

Reference

JR134951

Expiry date

01/01/0001

Jonathan Cunliffe Read more Shortlist Save this role
CRA

Salary

Location

Denmark, Copenhagen

Location

Copenhagen

Remote Working

Remote

Business Area

ICON Strategic Solutions

Job Categories

Clinical Monitoring

Job Type

Permanent

Description

We are currently seeking a Clinical Research Associate II to join our diverse and dynamic team. As a Clinical Research Associate II at ICON, you will play a pivotal role in designing and analyzing cli

Reference

JR137633

Expiry date

01/01/0001

Alison Burton

Author

Alison Burton
Read more Shortlist Save this role
Project Manager, Feasibility Site Activation

Salary

Location

Poland, Warsaw

Location

Sofia

Prague

Budapest

Dublin

Riga

Warsaw

Bucharest

Belgrade

Barcelona

Madrid

Bratislava

Reading

Tbilisi

Remote Working

Office or Home

Business Area

ICON Full Service & Corporate Support

Job Categories

Project Management

Job Type

Permanent

Description

Accountable for driving and accelerating the activation of global investigative sites in line with, or ahead of, the study's contractual timelines, within budgeted resources, with quality output, and

Reference

JR137323

Expiry date

01/01/0001

Magda Kozuszek Read more Shortlist Save this role
View all
List #1

Related stories

Two medics at ICON clinical research clinic
The Strategic Role of Site Selection and Activation in Clinical Trials

Teaser label

Industry

Content type

Blogs

Publish date

10/28/2025

Summary

Precision at the Outset: The Strategic Role of Site Selection and Activation in Clinical Trials The success of any clinical trial begins well before the first patient is enrolled. Behind every sit

Teaser label

Explore the critical role of site selection and activation in clinical trials.

Read more
Headshot of female
A Career Focused on Patients: Daniela's Journey at ICON

Teaser label

Our People

Content type

Blogs

Publish date

10/27/2025

Summary

Daniela’s Journey at ICON Daniela Gutierrez’s career at ICON has been a journey of transition, determination, and purpose. What began as a role in study start-up has evolved into a position deeply

Teaser label

Daniela shares insights into how collaboration, purpose, and innovation drive every part of her work.

Read more
Headshot of male
ICON Careers Spotlight: Chris Maguire, Director of Finance Business Partnering

Teaser label

Our People

Content type

Blogs

Publish date

10/15/2025

Summary

Chris Maguire’s Journey at ICON Over the past eight years at ICON, Chris Maguire has held six roles within the finance function, each expanding his expertise and sharpening his ability to support

Teaser label

Discover how Chris Maguire’s collaborative approach has shaped a rewarding career journey at ICON.

Read more
View all
List #1

Recently viewed jobs

View Jobs

Browse popular job categories below or search all jobs above